Details for New Drug Application (NDA): 205241
✉ Email this page to a colleague
The generic ingredient in HALOPERIDOL DECANOATE is haloperidol decanoate. There are twenty drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the haloperidol decanoate profile page.
Summary for 205241
| Tradename: | HALOPERIDOL DECANOATE |
| Applicant: | Gland |
| Ingredient: | haloperidol decanoate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 205241
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| HALOPERIDOL DECANOATE | haloperidol decanoate | INJECTABLE;INJECTION | 205241 | ANDA | Sagent Pharmaceuticals | 25021-831 | 25021-831-01 | 10 VIAL in 1 CARTON (25021-831-01) / 1 mL in 1 VIAL |
| HALOPERIDOL DECANOATE | haloperidol decanoate | INJECTABLE;INJECTION | 205241 | ANDA | Sagent Pharmaceuticals | 25021-833 | 25021-833-01 | 10 VIAL in 1 CARTON (25021-833-01) / 1 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 50MG BASE/ML | ||||
| Approval Date: | May 12, 2017 | TE: | AO | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 100MG BASE/ML | ||||
| Approval Date: | May 12, 2017 | TE: | AO | RLD: | No | ||||
Complete Access Available with Subscription
